CD80 (B7-1) and CD86 (B7-2): potential targets for immunotherapy?

Res Immunol. 1995 Mar-Apr;146(3):183-96. doi: 10.1016/0923-2494(96)80256-2.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Abatacept
  • Animals
  • Antigen-Presenting Cells / immunology
  • Antigens, CD / metabolism*
  • Antigens, Differentiation / metabolism
  • Autoimmunity
  • B7-1 Antigen / metabolism*
  • B7-2 Antigen
  • CD28 Antigens / metabolism
  • CTLA-4 Antigen
  • Clonal Anergy
  • Cyclosporine / pharmacology
  • Graft Rejection / immunology
  • Humans
  • Immunoconjugates*
  • Immunosuppression Therapy
  • Immunosuppressive Agents / pharmacology
  • Immunotherapy / methods*
  • In Vitro Techniques
  • Infections / immunology
  • Lymphocyte Activation
  • Membrane Glycoproteins / metabolism*
  • Neoplasms / therapy
  • Signal Transduction / immunology
  • T-Lymphocytes / immunology

Substances

  • Antigens, CD
  • Antigens, Differentiation
  • B7-1 Antigen
  • B7-2 Antigen
  • CD28 Antigens
  • CD86 protein, human
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Immunoconjugates
  • Immunosuppressive Agents
  • Membrane Glycoproteins
  • Abatacept
  • Cyclosporine